282,074 Becton, Dickinson and Company $BDX Shares Sold by Cooke & Bieler LP

Key Points

• Cooke & Bieler LP cut its Becton, Dickinson and Company stake by 24.8%, selling 282,074 shares during the third quarter and retaining 854,452 shares worth approximately $152.9 million.
• BD reported quarterly revenue of $4.98 billion and adjusted earnings of $3.23 per share, both exceeding analyst expectations; revenue increased 5.4% year over year. The company issued fiscal 2026 EPS guidance of $12.62–$12.72.
• BD shares opened at $194.29, near their 52-week high, while analysts maintained a consensus “Hold” rating with an average price target of $185.07. The company pays a $1.05 quarterly dividend, yielding about 2.2%.

Cooke & Bieler LP lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 24.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 854,452 shares of the medical instruments supplier's stock after selling 282,074 shares during the quarter. Becton, Dickinson and Company accounts for about 2.3% of Cooke & Bieler LP's holdings, making the stock its 8th largest position. Cooke & Bieler LP owned approximately 0.31% of Becton, Dickinson and Company worth $152,947,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Axxcess Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 27.7% during the third quarter. Axxcess Wealth Management LLC now owns 8,516 shares of the medical instruments supplier's stock valued at $1,524,000 after buying an additional 1,849 shares in the last quarter. Inlet Private Wealth LLC raised its position in Becton, Dickinson and Company by 5.0% during the third quarter. Inlet Private Wealth LLC now owns 29,180 shares of the medical instruments supplier's stock valued at $5,223,000 after buying an additional 1,400 shares during the period. Strengthening Families & Communities LLC lifted its stake in Becton, Dickinson and Company by 7.3% in the 3rd quarter. Strengthening Families & Communities LLC now owns 16,520 shares of the medical instruments supplier's stock worth $2,976,000 after acquiring an additional 1,122 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in Becton, Dickinson and Company by 34.0% in the 3rd quarter. Quadrant Capital Group LLC now owns 11,015 shares of the medical instruments supplier's stock worth $1,972,000 after acquiring an additional 2,794 shares in the last quarter. Finally, Capstone Capital Management Ltd purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth about $791,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $194.29 on Thursday. The business's 50-day moving average price is $184.73 and its two-hundred day moving average price is $164.54. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The company has a market capitalization of $53.53 billion, a P/E ratio of 58.52, a price-to-earnings-growth ratio of 13.07 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the firm posted $3.68 EPS. The business's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on BDX shares. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Jefferies Financial Group restated a "buy" rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Finally, Wolfe Research assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday. They issued an "outperform" rating on the stock. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.